MiniFAB Newsletter Edition #8 February 2012
Read the latest edition of the MiniFAB Newsletter here:
In it you'll find information about MiniFAB at MD&M West 2012 where we'll be at Booth 828, our CEO report, information on TearLab’s Regulatory successes, and an update on the bionic eye project.
The TearLab Osmalarity test overcomes two key regulatory hurdles
Early this month TearLab announced that they had received communication from the FDA indicating that the Agency had approved its petition for a waiver under CLIA for their Osmalarity System. The good news kept coming last week with the Centers for Medicare and Medicaid Services (CMS) publishing instructions for the reimbursement rate for the TearLab Osmalarity test to be revised to $23.25 per eye, across all US States. "With both the CLIA Waiver and uneven reimbursement obstacles now overcome, we can look forward to the adoption curve of this groundbreaking test steeping significantly in 2012," said TearLab’s CEO, Elias Vamvakas.
“This is great news for TearLab. Having both the CLIA waiver and reimbursement will allow many more people to use the diagnostic system, and we at MiniFAB are looking forward to ramping up our production to meet the increase in demand,” said MiniFAB’s Manufacturing Manager, Bas Garst.
MiniFAB currently manufactures 70,000 nanofluidic test cards per month for TearLab.
MiniFAB Newsletter Edition #7 November 2011
Read the latest edition of the MiniFAB Newsletter here:
In it you'll find information about MiniFAB at Medica 2011 where we'll be at our booth in Hall 2, Stand C06, our CEO report, an article by Erol on the subject of miniturisation tolerences, and a remark about our new multi-wavelength laser platform.
